Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R McKay

Showing results (821-830 of 932) with videos related to

Pageof 94
Sort By:
JCO Global Oncology|April 9, 2021
Tackling Diversity in Prostate Cancer Clinical Trials: A Report From the Diversity Working Group of the IRONMAN RegistryRana R McKay, Theresa Gold, Jelani C Zarif, et al.
JCO Precision Oncology|August 23, 2024
DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair GenesLaura S Graham, Nicholas C Henderson, Olesia Kellezi, et al.
Prostate Cancer and Prostatic Diseases|February 22, 2024
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaborationZeynep B Zengin, Nicholas C Henderson, Joseph J Park, et al.
ESMO Open|May 19, 2026
EV-103 dose escalation/cohort A: 5-year follow-up of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced/metastatic urothelial carcinomaJ E Rosenberg, P H O'Donnell, D P Petrylak, et al.
European Urology Oncology|November 3, 2022
Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumChun Loo Gan, Jiaming Huang, Elizabeth Pan, et al.
Medrxiv : the Preprint Server for Health Sciences|May 7, 2026
Androgen Deprivation Therapy (ADT) and Radiotherapy (RT) with Imaging Evaluation Longitudinally (ARIEL) trial: protocol, early results, and implications of neoadjuvant ADT for focal RT boost in prostate cancerYuze Song, Mariluz Rojo Domingo, Lily Nguyen, et al.
Cell Reports|September 8, 2021
Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancerAlok K Tewari, Alexander T M Cheung, Jett Crowdis, et al.
The Prostate|April 1, 2021
Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancerElisa M Ledet, Earle F Burgess, Alexandra O Sokolova, et al.
European Urology Focus|December 8, 2024
Efficacy of Treatments After Lenvatinib in Patients with Advanced Renal Cell CarcinomaJustine Panian, Caiwei Zhong, Sharon H Choi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2024
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With PembrolizumabMatthew I Milowsky, Peter H O'Donnell, Christopher J Hoimes, et al.
Pageof 94

Showing results (821-830 of 932) with videos related to

Sort By:
Pageof 94
JCO Global Oncology|April 9, 2021
Tackling Diversity in Prostate Cancer Clinical Trials: A Report From the Diversity Working Group of the IRONMAN RegistryRana R McKay, Theresa Gold, Jelani C Zarif, et al.
JCO Precision Oncology|August 23, 2024
DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair GenesLaura S Graham, Nicholas C Henderson, Olesia Kellezi, et al.
Prostate Cancer and Prostatic Diseases|February 22, 2024
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaborationZeynep B Zengin, Nicholas C Henderson, Joseph J Park, et al.
ESMO Open|May 19, 2026
EV-103 dose escalation/cohort A: 5-year follow-up of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced/metastatic urothelial carcinomaJ E Rosenberg, P H O'Donnell, D P Petrylak, et al.
European Urology Oncology|November 3, 2022
Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumChun Loo Gan, Jiaming Huang, Elizabeth Pan, et al.
Medrxiv : the Preprint Server for Health Sciences|May 7, 2026
Androgen Deprivation Therapy (ADT) and Radiotherapy (RT) with Imaging Evaluation Longitudinally (ARIEL) trial: protocol, early results, and implications of neoadjuvant ADT for focal RT boost in prostate cancerYuze Song, Mariluz Rojo Domingo, Lily Nguyen, et al.
Cell Reports|September 8, 2021
Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancerAlok K Tewari, Alexander T M Cheung, Jett Crowdis, et al.
The Prostate|April 1, 2021
Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancerElisa M Ledet, Earle F Burgess, Alexandra O Sokolova, et al.
European Urology Focus|December 8, 2024
Efficacy of Treatments After Lenvatinib in Patients with Advanced Renal Cell CarcinomaJustine Panian, Caiwei Zhong, Sharon H Choi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2024
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With PembrolizumabMatthew I Milowsky, Peter H O'Donnell, Christopher J Hoimes, et al.
Pageof 94